We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
The upcoming report from Eli Lilly (LLY - Free Report) is expected to reveal quarterly earnings of $7.26 per share, indicating an increase of 117.4% compared to the year-ago period. Analysts forecast revenues of $17.78 billion, representing an increase of 39.7% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 2.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Lilly metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total' to come in at $194.95 million. The estimate points to a change of -13.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Humulin' will likely reach $160.40 million. The estimate indicates a year-over-year change of -7.4%.
Analysts' assessment points toward 'Revenue- Humalog' reaching $482.05 million. The estimate indicates a year-over-year change of -10.3%.
The collective assessment of analysts points to an estimated 'Revenue- Forteo' of $60.52 million. The estimate points to a change of -9.1% from the year-ago quarter.
The consensus estimate for 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- US' stands at $80.13 million. The estimate indicates a year-over-year change of -20%.
It is projected by analysts that the 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- ROW' will reach $114.82 million. The estimate indicates a year-over-year change of -7.9%.
The average prediction of analysts places 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- US' at $596.53 million. The estimate points to a change of -22.6% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- ROW' should arrive at $301.83 million. The estimate indicates a change of -7% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Jardiance (Empagliflozin/BI 10773)- US' will reach $294.21 million. The estimate suggests a change of -5% year over year.
According to the collective judgment of analysts, 'Revenue- Jardiance (Empagliflozin/BI 10773)- ROW' should come in at $476.88 million. The estimate suggests a change of -32.3% year over year.
Analysts predict that the 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- US' will reach $46.41 million. The estimate indicates a change of +0.2% from the prior-year quarter.
Analysts forecast 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- ROW' to reach $190.17 million. The estimate points to a change of +4.3% from the year-ago quarter.
Over the past month, Lilly shares have recorded returns of +0.7% versus the Zacks S&P 500 composite's +9.3% change. Based on its Zacks Rank #3 (Hold), LLY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
The upcoming report from Eli Lilly (LLY - Free Report) is expected to reveal quarterly earnings of $7.26 per share, indicating an increase of 117.4% compared to the year-ago period. Analysts forecast revenues of $17.78 billion, representing an increase of 39.7% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 2.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Lilly metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total' to come in at $194.95 million. The estimate points to a change of -13.3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Humulin' will likely reach $160.40 million. The estimate indicates a year-over-year change of -7.4%.
Analysts' assessment points toward 'Revenue- Humalog' reaching $482.05 million. The estimate indicates a year-over-year change of -10.3%.
The collective assessment of analysts points to an estimated 'Revenue- Forteo' of $60.52 million. The estimate points to a change of -9.1% from the year-ago quarter.
The consensus estimate for 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- US' stands at $80.13 million. The estimate indicates a year-over-year change of -20%.
It is projected by analysts that the 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- ROW' will reach $114.82 million. The estimate indicates a year-over-year change of -7.9%.
The average prediction of analysts places 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- US' at $596.53 million. The estimate points to a change of -22.6% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- ROW' should arrive at $301.83 million. The estimate indicates a change of -7% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Jardiance (Empagliflozin/BI 10773)- US' will reach $294.21 million. The estimate suggests a change of -5% year over year.
According to the collective judgment of analysts, 'Revenue- Jardiance (Empagliflozin/BI 10773)- ROW' should come in at $476.88 million. The estimate suggests a change of -32.3% year over year.
Analysts predict that the 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- US' will reach $46.41 million. The estimate indicates a change of +0.2% from the prior-year quarter.
Analysts forecast 'Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- ROW' to reach $190.17 million. The estimate points to a change of +4.3% from the year-ago quarter.
View all Key Company Metrics for Lilly here>>>Over the past month, Lilly shares have recorded returns of +0.7% versus the Zacks S&P 500 composite's +9.3% change. Based on its Zacks Rank #3 (Hold), LLY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .